We have previously identified the Legionella 19-kDa peptidoglycan-associated lipoprotein (PAL) as a speciescommon immunodominant antigen. We describe here for the first time the excretion and detection of the PAL antigen in infected urine specimens, which is useful for the diagnosis of Legionnaires' disease. Rabbit anti-PAL immunoglobulin G (IgG) antibody was produced by immunization with the purified, recombinant PAL of Legionella pneumophila serogroup 1 and used in the PAL antigen capture enzyme-linked immunosorbent assay (ELISA) to detect urinary PAL antigen. A soluble-antigen capture ELISA using rabbit IgG antibodies against Legionella soluble antigens was prepared independently and used as a broad-spectrum standard test to detect soluble antigens of several Legionella species. Urine samples were obtained from guinea pigs experimentally infected with each of L. pneumophila serogroups 1, 3, and 6, and other Legionella species. The absorbance values of the PAL antigen ELISA highly correlated with those of the soluble-antigen ELISA in infected urine samples, with a correlation coefficient of 0.84 (P < 0.01). When applied to 17 infected urine samples and 67 negative controls from guinea pigs, the sensitivity and specificity of the PAL antigen capture ELISA were 88.2 and 95.5%, respectively. Compared to the commercial Biotest enzyme immunoassay, the PAL antigen ELISA was more efficient for detecting pneumophila non-serogroup 1 and nonpneumophila species. None of the 161 control human urine specimens obtained from healthy adults and patients with either non-Legionella pneumonia or urinary tract infections tested positive in the PAL antigen ELISA. The present study shows that the Legionella PAL is a very useful broad-spectrum antigen for urinary diagnostic testing. Moreover, since recombinant PAL antigen can be produced more efficiently than the soluble antigens, the development of a broad-spectrum diagnostic immunoassay based on the detection of the PAL antigen appears to be warranted.
Legionella is an important cause of both community-acquired and nosocomial pneumonia. Legionella pneumonia may be severe and is potentially fatal in elderly and immunocompromised patients, and rapid diagnosis and early antibiotic treatment are required (17, 23) . However, the diagnosis of Legionella pneumonia can be difficult because clinical manifestations and radiographic findings are nonspecific, and conventional laboratory tests, including culturing of the organism, direct fluorescent antibody staining of the bacterium, and serum antibody detection have suboptimal sensitivities, with results that are not rapidly available (8, 9) .
Detection of soluble antigens in the urine of patients with Legionella pneumonia was first described in 1979 (3, 26) . Over the intervening years, Legionella urinary antigen detection methods using the techniques of enzyme immunoassay (EIA) and radioimmunoassay have been extensively studied and have proven to be the most powerful diagnostic methods (4, 5, 18, 22, 24) . The specificity for these tests has been reported to be 100%, and the sensitivity has been shown to vary between 70 and 100% (15) . The advantages of these methods include ease of urine collection, the ability to detect antigen after initiation of antibiotic therapy, and the ability to obtain results quickly. Two commercial EIA kits, Binax EIA (Binax, Portland, Maine) and Biotest EIA (Biotest AG, Dreieich, Germany), have been widely used since being marketed in 1996 and 1997, respectively, and a new Bartels EIA (Bartels, Inc., Trinity Biotech Company, Wicklow, Ireland) has been introduced recently. These EIAs have been reported to be sensitive and specific in many clinical studies (2, 6, 7, 11, 12, 16, 21) . However, several authors pointed out that the available tests showed excellent sensitivity to L. pneumophila serogroup 1 antigen but variable sensitivity to L. pneumophila non-serogroup 1 and other Legionella species (2, 6, 7, 12, 16) . Although the L. pneumophila serogroup 1 is the predominant cause of legionellosis in most geographic areas, other pneumophila serogroups and other Legionella species are being recognized with increasing frequency, therefore questioning the broadspectrum utility of these tests (27) . The commercial EIA tests are direct sandwich assays that use polyclonal rabbit antibodies specific to L. pneumophila serogroup 1 or reactive to soluble extracts of L. pneumophila serogroups and other species as the capture and detection antibodies. Therefore, the value of urinary antigen detection assays would be significantly enhanced to diagnose Legionella pneumonia if a Legionella species-common, surface antigen is targeted.
The 19-kDa peptidoglycan-associated lipoprotein (PAL) of L. pneumophila was sequenced and characterized as the most prominent surface antigen in 1991 (10, 19) and retrospectively seems to be same as the 19-kDa common Legionella outer membrane antigen that was cloned before (13) . However, whether or not the L. pneumophila PAL will be diagnostically useful is open to investigation. We have previously overexpressed and purified the recombinant Legionella PAL and demonstrated that the Legionella PAL is a strong antibody inducer in rabbits and mice. The PAL is also highly conserved among Legionella species (30) . The aim of the present study is to characterize the Legionella species-common PAL as a potential broad-spectrum urinary antigen to diagnose Legionnaires' disease. We developed an enzyme-linked immunosorbent assay (ELISA) using the capture antibody specific to the PAL antigen and demonstrated that the Legionella PAL antigen, excreted in urine samples from guinea pigs infected with pneumophila and nonpneumophila species and serogroups, was detected efficiently by the PAL antigen capture assay.
MATERIALS AND METHODS
Guinea pig infection and urine sample collection. Male Hartley strain guinea pigs (300 to 400 g) were inoculated intratracheally with ca. 10 9 CFU of legionellae suspended in 0.5 ml of phosphate-buffered saline (PBS), as previously described (29) . A couple of guinea pigs in a group were inoculated with each strain of pneumophila and nonpneumophila species and serogroups. Animals were observed twice daily after inoculation for signs of illness: fever, ruffled fur, labored respirations, weight loss, and crusting of conjunctival fluid. Fever was defined as two consecutive rectal temperatures that exceeded 40°C. Urine samples were collected from the control and infected animals by using a metabolic cage and stored in aliquots at Ϫ70°C before use. Urine samples from the infected animals were obtained between days 1 and 5 after inoculation.
A couple of guinea pigs infected with L. pneumophila serogroup 1 were sacrificed 3 days after infection. Lungs were fixed in 10% formalin. Tissues were embedded in paraffin, sectioned at 6 mm, stained with hematoxylin and eosin, and examined for the pathological findings of Legionnaires' disease. Urine samples obtained from these animals were used as positive controls in the ELISA.
Human urine samples. Human urine samples were collected from three control groups; 86 healthy adults who visited the health center of Korea University Hospital, 59 patients with nonlegionella pneumonia enrolled in the prospective, multi-center study to identify the etiology of community acquired pneumonia in Korea, and 16 patients with urinary tract infection. Urine samples were stored at Ϫ70°C before use.
Preparation of the recombinant Legionella PAL. The recombinant PAL antigen of L. pneumophila serogroup 1 was overproduced in Escherichia coli and purified by affinity chromatography, as described previously (30 were prepared by the method described previously (3, 24) . Each Legionella strain was grown on buffered charcoal yeast extract-alpha-ketoglutarate (BCYE␣) agar for 48 h and harvested in 3 ml of 0.05 M PBS (pH 7.4). The cell suspensions were centrifuged, and 0.5-ml samples of wet packed cells were autoclaved for 1 h at 100°C and then left at 4°C for 10 days to extract the soluble antigens. The suspensions were centrifuged at 1,200 ϫ g for 10 min, and the collected supernatants were used for rabbit immunization and immunoblot assay.
Anti-PAL antigen and anti-soluble-antigen IgG preparation. Production and purification of anti-PAL immunoglobulin G (IgG) of L. pneumophila serogroup 1 has been described previously (30) . An adult New Zealand White rabbit was injected with 100 g of truncated recombinant PAL into the subscapular space and several subcutaneous sites on the back at 2-week intervals for 2 months. Hyperimmune sera were collected, and IgG was purified by fast-protein liquid chromatography (Pharmacia Biotech, Inc.) in a protein A-Superose HR 10/2 column (Pharmacia LKB). The protein concentration was determined by using the Bio-Rad protein assay kit (Bio-Rad Laboratories, Hercules, Calif.). The purified IgG was identified by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and used for experiments.
Production of anti-soluble-antigen IgG was done by the method described previously (24) . A patient isolate of L. pneumophila serogroup 1 was prepared as whole-cell antigen at a density of 40 IU, and combined with soluble antigens from the 12 Legionella strains in an equal volume. One milliliter of antigen was injected into a rabbit according to the immunization protocol described earlier (24) . The following purification steps were the same as described above.
Enzyme conjugate preparation. Horseradish peroxidase (HRP; Type VI; Sigma Chemical Co., St. Louis, Mo.) was prepared as described previously (25) . Fast-protein liquid chromatography-purified IgG antibodies were dialyzed against 0.01 M sodium bicarbonate (pH 9.5). Conjugation of HRP to the purified IgG antibodies was performed according to the procedures described by Nakane and Kawaoi (20) , with the input molar HRP/IgG ratio of 5.6. The conjugates were dialyzed against PBS and purified by Sephadex G-200 size exclusion chromatography. The conjugates were ultrafiltrated, stored at Ϫ20°C, and supplemented with 1% (wt/vol) bovine serum albumin (Fraction V; Sigma).
Antigen capture ELISA. Rabbit anti-soluble-antigen IgG and anti-PAL IgG were used as capture and detection antibodies for the soluble-antigen-based ELISA and the PAL antigen-based ELISA, respectively. Polyvinyl chloride Ubottom microtiter plates (Becton Dickinson, Franklin Lakes, N.J.) were used in the ELISA. A 100-l portion of anti-PAL or anti-soluble-antigen IgG at a concentration of 1 mg/ml in PBS, determined by a boxed titration with each antigen, was applied to coat each well of the microtiter plate. Coating was carried out overnight at 4°C. The plates were washed three times with PBS (pH 7.4) with 0.05% Tween 20 (PBS-T) and blocked with 200 l of blocking buffer (0.5% casein in 100 mM Tris [pH 7.6]) overnight at 4°C. All urine samples were boiled for 1 min in a water bath, centrifuged at 1,200 ϫ g for 10 min, and added to duplicate wells and incubated at 37°C for 1 h. After the plates were washed, anti-PAL or anti-soluble-antigen IgG-HRP conjugates, diluted 1:1,000 in 0.5% casein in 100 mM Tris (pH 7.6)-0.1% Tween 20, were added to the wells. After incubation at 37°C for 1 h, the plates were washed again and incubated with the substrate TMB (3,3Ј,5,5Ј-tetramethylbenzidine). The plates were incubated at 37°C for 1 h in the dark, and color development was stopped by the addition of 50 l of 1 N H 2 SO 4 . The absorbance was measured in a VERSAmax reader at 450 nm (Molecular Devices Co., Sunnyvale, Calif.).
Biotest Legionella urinary antigen EIA. The Biotest Legionella urinary antigen EIA (Biotest Ag, Dreieich, Germany) is a direct sandwich assay that uses polyclonal rabbit antibodies which react with antigens of all L. pneumophila serogroups, as well as with antigens of other Legionella species, as the capture and detection antibodies. The test was performed according to the manufacturer's instructions. The cutoff value was calculated as the mean absorbance of the negative controls plus 0.200. Urine samples with an extinction value equal to or greater than the cutoff value were considered positive.
Immunoblot analysis. Protein samples were separated by SDS-PAGE and electrophoretically transferred to nitrocellulose membranes (Amersham Life Sciences) in a buffer containing 39 mM glycine, 48 mM Tris-HCl (pH 8.3), 0.5% SDS, and 20% methanol. The membrane was preequilibrated with TBST (10 mM Tris-HCl [pH 8.0], 150 mM NaCl, 0.05% Tween 20) containing 5% (wt/vol) skim milk for 1 h and further incubated with rabbit immune sera for 1 h at room temperature. After three washes with TBST, the membrane was incubated for 30 min at room temperature with anti-rabbit IgG conjugated with HRP (Amersham). After three washes, a positive image was developed on X-ray film (Agfa, Mortsel, Belgium) by using ECL detection reagents (Amersham).
Statistical analysis. Each antigen determination was performed in duplicate, and the results were expressed as the mean absorbance for each determination. The soluble-antigen capture ELISA results served as the standard test. The positive threshold was calculated by using the mean absorbance of the negative controls plus 3 standard deviations (SDs). The results obtained by the PAL antigen capture ELISA and the soluble-antigen capture ELISA were compared by Pearson correlation analysis. The PAL antigen capture ELISA was evaluated in terms of its sensitivity and specificity. The sensitivity, specificity, and positive and negative predictive values were calculated by using each cutoff value. The means of values were compared by using the Student t test. All statistical analyses were done by using the SAS (version 8.0) package program. Fig. 1 ). All species tested showed an ϳ19-kDa prominent protein that reacted strongly to anti-PAL IgG, even though each PAL was not distinctive in the SDS-PAGE. We also identified that the purified, recombinant Legionella PAL antigen showed strong reactivity to anti-soluble-antigen IgG antibody in an immunoblot analysis (data not shown). This result indicates that the Legionella PAL antigen is an immunodominant component of soluble antigens and is a highly conserved common antigen among pneumophila and nonpneumophila species. This observation supports the idea that the Legionella PAL can be used as an alternative target antigen in the urinary diagnostic immunoassay for Legionnaires' disease.
RESULTS

PAL antigen is an immunodominant component of
Preparation of soluble-antigen capture ELISA as a broadspectrum standard test. For the identification of positive urine samples, the soluble-antigen capture ELISA with anti-solubleantigen IgG was prepared independently in the present study as a broad-spectrum standard test. The positive threshold for the assay was 0.22 (0.12 ϩ 0.10 SD) (unless otherwise stated, results are given as the mean absorbance plus 3 SDs), determined by using 67 samples from uninfected control animals. Urine samples were obtained from guinea pigs inoculated with each of L. pneumophila serogroups 1, 3, and 6, L. jordanis; L. oakridgensis; L. anisa; L. gormanii; and L. sainthelensi. All animals inoculated, except for one inoculated with L. gormanii, showed signs of illness. A couple of animals infected with L. pneumophila serogroup 1 were sacrificed and confirmed for the pathological changes: lung tissue exhibited focal, acute peribronchial pneumonia characterized by alveolar and septal infiltration with neutrophils and macrophages on the light microscopic findings (data not shown). The soluble-antigen ELISA was performed on 17 specimens from each of the infected animals collected between days 1 and 5 after inoculation. All 17 urine samples were determined to be positive, with an absorbance range of 0.47 to 3.0 (Fig. 2) , indicating that the soluble-antigen ELISA could serve as a valid standard test.
Evaluation of the Legionella PAL antigen capture ELISA as a diagnostic assay. Preliminary experiments were performed to evaluate anti-PAL IgG for the ability to serve as an adequate Legionella PAL antigen-capture reagent, and we identified it as a satisfactory capture antibody because it was able to capture the respective antigen with a range of 0.01 to 10 g/ml (data not shown). To identify whether the PAL antigen was excreted in infected urine specimens, we performed the PAL antigen capture ELISA on 17 infected urine samples from guinea pigs and compared the results obtained with the PAL antigen and to those obtained with the soluble-antigen assays. The mean absorbance values Ϯ the SDs obtained by the soluble-antigen and the PAL antigen capture assays were 1.46 Ϯ 0.89 and 0.25 Ϯ 0.15, respectively. The correlation of the absorbance values from the two antigen assays is shown in Fig. 2 . The correlation coefficient was 0.84 (P Ͻ 0.001). On the basis of the result from the soluble-antigen capture ELISA as a standard, the PAL antigen was excreted in urine as a component of Legionella soluble antigens and detected efficiently by the PAL antigen capture assay.
The performance of the PAL antigen ELISA was evaluated on 17 infected urine samples (8 from pneumophila serogroups and 7 from nonpneumophila species) and 67 controls obtained from the uninfected animals. The overall sensitivity and specificity were 88.2 and 95.5%, respectively, when a cutoff value of 0.10 was chosen. The positive predictive value was 83.3%, and the negative predictive value was 97.0% (Table 1) . With this cutoff value, all 8 pneumophila urine samples were positive, with an absorbance range of 0.13 to 0.49, and 3 of 67 controls also were positive (sensitivity, 100.0%; specificity, 95.5%). In the case of nonpneumophila species, 7 of 9 infected urine samples were positive, with an absorbance range of 0.10 to 0.35 (sensitivity, 77.8%; specificity, 95.5%).
On the basis of these findings, we compared the results of the PAL antigen ELISA with those obtained by the commercial Biotest Legionella urinary antigen EIA (Biotest AG) (Table 2). For 17 infected urine samples, the Biotest EIA could detect only L. pneumophilia serogroup 1-infected samples. Three samples from L. pneumophila non-serogroup 1 and five samples from nonpneumophila species that were positive in the PAL antigen ELISA were negative in the Biotest EIA.
We also evaluated the PAL antigen capture ELISA for cross-reactivity. A total of 161 human urine samples were included in the experiment: 16 urine samples collected from patients with urinary tract infection due to E. coli, Klebsiella pneumoniae, methicillin-resistant Staphylococcus aureus, Enterococcus faecium, or Pseudomonas aeruginosa, etc.; 59 samples from patients with non-Legionella pneumonia; and 86 samples from healthy adults. All of these control samples were determined to be negative by the PAL antigen ELISA (Table  3) .
DISCUSSION
In this study we characterized the 19-kDa PAL antigen of Legionella species as a potential urinary diagnostic antigen for Legionnaires' disease. We developed the Legionella PAL antigen capture ELISA to detect the PAL antigen excreted in infected urine, and we evaluated the sensitivity and specificity of the assay with urine samples obtained from guinea pigs infected with pneumophila and nonpneumophila species and serogroups.
Legionnaires' disease has been described as overtreated and underdiagnosed (1), a reflection of the limitations of available diagnostic tests. Urinary antigen testing to detect Legionella antigen has proven the most powerful diagnostic method (4, 5, 15, 16, 18, 22, 24) , and the commercially available tests have been widely used. However, the main drawback to the available urinary antigen tests is that they only detect the soluble antigen of L. pneumophila serogroup 1 but do not efficiently detect L. pneumophila non-serogroup 1 and other Legionella species (2, 12) . Moreover, concerns have been raised over the sensitivity of urinary antigen testing, as the prevalence of serogroup 1 decreases (27) . Since the soluble antigen detected by these tests has been known as lipopolysaccharide (LPS) (28), the sensitivity may have been influenced by strain differences of LPS or other immunogens, as suggested elsewhere (4, 6, 14) . Therefore, the value of urinary antigen tests would be enhanced if Legionella infections other than L. pneumophila serogroup 1 infections could also be detected. A broad-spectrum ELISA was developed by using IgG antibodies raised by soluble culture extracts from multiple Legionella species and serogroups and detected antigenuria in patients with laboratorydiagnosed Legionnaires' disease caused by L. pneumophila serogroups 1, 3, 4, 6, and 8; by L. micdadei; or by L. longbeachae serogroup 1 (24) . The test is not yet commercially available.
We have shown that Legionella PAL is an immunodominant component of the soluble extracts from Legionella species and also highly conserved among the Legionella species. We have previously shown that this lipoprotein most strongly reacted to the rabbit anti-soluble-antigen polyclonal antibody absorbed with Legionella LPS during characterization of Legionella soluble antigens in an immunoblot analysis (data not published), allowing us to consider the PAL as a potential urinary diagnostic antigen. Although the pal gene has not been amplified from L. micdadei and L. jordanis by using the primer set derived from the pal gene sequence of L. pneumophila serogroup 1 (30), the 19-kDa protein antigen has been clearly shown with Legionella species tested, including L. micdadei and L. jordanis. This suggests that the anti-PAL IgG used contains antibodies to the common epitopes of the PAL harbored by all Legionella species.
We have prepared independently and used the soluble-antigen capture ELISA as a broad-spectrum standard test to validate the PAL antigen for a diagnostic urinary antigen. The The PAL antigen capture ELISA was ca. 76.5 to 88.2% sensitive and ca. 95.5 to 98.5 specific according to the cutoff values determined and was thus comparable to that of the broad-spectrum assay reported previously (with a sensitivity of 70% and a specificity of nearly 100%) (24) . The reasons for this remain to be elucidated, but sensitivity may depend on the concentration of the antigen excreted in urine samples. There is a lack of information on the factors that influence the concentration of the soluble antigen released and achieved in urine specimens. We did not apply the PAL antigen capture ELISA to patients' urine samples infected with Legionella in the present study due to a lack of specimen availability. The clinical performance of the PAL antigen assay should be evaluated in the future.
We have also shown that the PAL antigen capture ELISA showed better sensitivity than the commercial Biotest EIA, especially in detecting urinary antigen from L. pneumophila nonserogroup 1 strain and other Legionella species. These findings are similar to those of previous reports, although the commercial kit is manufactured to detect all of the serogroups of L. pneumophila, as well as antigens from other Legionella species. Further evaluation is needed for comparative test performance on culture-proven Legionnaires' disease.
We have observed that cross-reactivity was not noted in analyses when 161 human urine samples from healthy subjects and from subjects with non-Legionella pneumonia and urinary tract infections were tested with the PAL antigen capture ELISA, but a few negative control urine samples from guinea pigs tested positive near the cutoff value of absorbance. These reactions may be due to diagnostically irrelevant components of guinea pig urine specimens or other technical factors in performing ELISA, which needs to be reevaluated in further studies with larger sample series and clinical Legionnaires' disease.
In conclusion, this is the first study demonstrating the excretion and detection of Legionella PAL antigen in infected urine specimens and evaluating the PAL antigen capture ELISA for the diagnosis of Legionnaires' pneumonia. The Legionella PAL antigen capture ELISA was able to diagnose 88.2% of urine samples tested and should be considered as a broad-spectrum assay to detect both pneumophila and nonpneumophila species and serogroups. Its diagnostic accuracy could be enhanced to 100% if concentrated urine samples are used. The results reported here suggest that the Legionella PAL is a circulating soluble surface antigen and is excreted in urine similar to the dynamics of other soluble antigens. Therefore, it can serve as an alternative broad-spectrum antigen to the soluble antigens to enhance the value of the urinary antigen assay. In addition, the PAL antigen is readily available as a recombinant protein that acts as a strong antibody inducer. Thus, developing the PAL antigen capture ELISA is warranted to improve the diagnosis of Legionnaires' disease.
